Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of HEC169584 in Healthy Subjects
NCT07099118Phase 1Recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC169584 in Nonalcoholic steatohepatitis (NASH) (11 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Adverse Events up to 27 days. Started Sep 2025; status: recruiting.
02
Drugs
HEC169584
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT07099118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07099118.